Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab after autologous SCT in high-risk AML
NCT02771197Phase 2Completed
- Sponsor
- Northside Hospital
- Start
- Sep 2016
- Primary completion
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in acute myeloid leukemia (AML), sponsored by Northside Hospital. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02771197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771197.